First author | Year | Country | No. of contacts* (age range) | No. of contacts with CT or PET abnormalities | Bacterial/molecular Testing | Anti-TB treatment | Follow-up without anti-TB treatment/Developing TB during follow-up | |||
---|---|---|---|---|---|---|---|---|---|---|
Any | Lung** parenchyma | Mediastinal LN | Tested | Positive | ||||||
Chest CT | ||||||||||
Delacourt [13] | 1993 | France | 15 (0–10 s) | 9 [60%] | 0 [0%] | 9 [60%] | Not separable | Not described | Not described | |
Duran [14] | 1996 | Spain | 22 (0–10 s) | 14 [64%] | 4 [18%] | 14 [64%] | 8 | 4 [50%] | Not described | Not described |
Katakura [15] | 1999 | Japan | 4 (0Â s) | 4 [100%] | 3 [75%] | 1 [25%] | 4 | 0 [0%] | 4 [100%] | None |
Baghaie [16] | 2005 | Iran | 64 (4–14) | 25 [39%] | Not separable | Not separable | Not described | Not described | ||
Yoshiyama [17] | 2008 | Japan | 21 (20–40 s) | 7 [33%] | 7 [33%] | 0 [0%] | 7 | 1 [14%] | 7 [100%] | None |
Lew [18] | 2009 | Korea | 46 (16–20) | 12 [26%] | 12 [26%] | 0 [0%] | 11 | 0 [0%] | 11 [92%] | 1†/1 |
Lee [19] | 2010 | Korea | 39 (20 s) | 9 [23%]‡ | 9 [23%] | 0 [0%] | 9 | 3 [33%] | 9 [100%] | None |
Hirama [20]‡†| 2011 | Japan | 34 (adults) | 4 [12%] | 4 [12%] | 0 [0%] | Not described | 4 [100%] | None | |
Garrido [21] | 2012 | Spain | 11 (< 4 years) | 9 [81%] | 7 [64%] | 9[81%] | 11 | 1 [9%] | 11 [100%] | None |
Fujikawa [22] | 2014 | Japan | 110 (20–50 s) | 12 [11%] | 12 [11%] | 0 [0%] | 12 | 3 [25%] | 12 [100%] | None |
Catho [23] ‡‡ | 2015 | France | 5 (child) | 1 [20%] | 1 [20%] | 1 [20%] | 1 | 1 [100%] | 1 [100%] | None |
Lu [24] | 2016 | China | 27 (10Â s) | 6 [22%] | 6 [22%] | 0 [0%] | 6 | 0 [0%] | 6 [100%] | None |
Ziemele [25] | 2017 | Latvia | Unknown (0–17) | 145 [unknown] | Not separable | 145 | 7 [5%] | 145 [100%] | None | |
Lee [26]‡‡†| 2017 | Korea | 6 (30 s) | 2 [33%] | 2 [33%] | 0 [0%] | 2 | 0 [0%] | 0 [0%] | 2/1 |
Shimizu [27] | 2017 | Japan | 52 (0–10 s) | 10 [19%] | Not separable | 10 | 0 [0%] | Not separable | None | |
Moreno-Ballester [28] | 2018 | Spain | 52 (0–10 s) | 27 [52%] | 17 [33%] | 27 [52%] | Not described | 27 [52%] | None | |
Yoshiyama [29] | 2019 | Japan | 229 (10–80 s) | 24 [10%] | 24 [10%] | 0 [0%] | 24 | 7 [29%] | 23 [96%] | 1/follow-up loss at 3 mo |
Zhou [30] | 2019 | China | 59 (10Â s) | 51 [86%] | Not separable | Not separable | 35 [69%] | 15***/1 | ||
Yoon [31] ‡‡‡ | 2020 | Korea | 17 (50–70 s) | 14 [82%] | 14 [82%] | 0 [0%] | Not described | 0 [0%] | 14/0 | |
Wang [32] | 2020 | China | 135 (10–60 s) | 4 [3%] | Not separable | 4 | 0 [0%] | 4 [100%] | None | |
Mok [33] | 2021 | Korea | 72 (adults) | 14 [19%] | 14 [19%] | 0 [0%] | 14 | 1 [7%] | 0 [0%] | 14***/1 |
18F-FDG PET/CT | ||||||||||
Ghesani [34] | 2014 | USA | 5 (20–40 s) | 3 [60%]‡‡‡†| 0 [0%] | 3 [60%] | Not described | 0 [0%] | 3***/0 | |
Esmail [35]‡‡‡‡ | 2016 | UK | 35 (20–30 s) | 16 [46%] | 10 [29%] | 16 [46%] | 16 | 0 [0%] | 0 [0%] | 16***/4 |
18F-FDG PET/MRI | ||||||||||
Molton [36] | 2019 | Singapore | 30 (0–50 s) | 9 [30%] | 4 [13%] | 6 [20%] | Not described | 0 [0%] | 9***/0 | |
Naftalin [37] | 2020 | Singapore | 3 (20–50 s) | 2 [67%] | 2 [67%] | 2 [67%] | Not described | Not described | Not described |